CINAHL, Psycinfo. This timeframe was chosen to capture the post-erythropoietin era dialysis populations.
The search strategy and process of obtaining the final articles, including exclusions, justifications and final selections, is outlined in Figure 1 . Search terms were chosen to identify the dialysis cohort and common upper and lower GI symptoms, however studies reporting on any GI symptom were eligible for inclusion.
Inclusion/exclusion criteria and study selection
The inclusion criteria were defined as follows: studies on the adult maintenance dialysis population (either HD or PD), one or more of the following primary outcomes reported or measured (bloating, pain, stool consistency, diarrhoea, constipation, excessive gas, irritable bowel syndrome (IBS), diverticulitis or GI symptoms) and observational studies or randomized controlled trials.
The exclusion criteria were: animal studies, non-English language, duplications, no report of GI symptoms, GI infections (e.g. parasites, Clostridium difficile), non-dialysis populations, reviews, commentaries, letters to editors, guidelines, and dialysis for acute kidney injury.
Data extraction
The primary reviewer extracted information from each of the articles and collated the data into a Microsoft Excel spreadsheet. A secondary reviewer crosschecked each entry and any discrepancies were resolved through mutual consensus and/or third party review. The data collected included: demographic data of the HD, PD and control groups, the country of origin, aims, design, duration, The search terms used were: 'bowel' OR 'constipation' OR 'diarrhoea' OR 'bloating' OR 'abdominal pain' OR 'gastroparesis' OR 'flatulence' OR 'irritable bowel syndrome' OR 'gut health' OR 'stool consistency' OR 'gastric emptying' OR 'chronic constipation' OR gastrointestinal symptoms AND 'dialysis' OR 'peritoneal dialysis' OR 'haemodialysis' OR 'hemodialysis' OR 'renal dialysis' OR 'renal replacement therapy' OR 'continuous ambulatory peritoneal dialysis' OR 'home dialysis'. Other search terms also included 'frequency' OR 'prevalence'.
methodology, tests and results, including the severity of GI symptoms, and diagnostic tools.
Quality assessment
Two independent reviewers critically appraised each article using the Newcastle-Ottawa Scale (NOS). 7 Cohort studies were graded out of 10. An adapted version was used for cross-sectional studies, which scored up to eight. Articles were scored on selection, comparability and outcome. Selection assesses the quality of the sample, the response rate and the validity of the measurement tools. Comparability appraises the comparison groups and how well confounders were controlled. The outcome pertains to how the outcome was assessed and the statistical tests used.
RESULTS

Search results
The search results are shown in Figure 1 .
Characteristics of selected studies
The dialysis populations, diagnostic tools used and key findings of each study can be found in Table 1 . There were 24 cross-sectional and six cohort studies, all published between 1998 and 2016. Sixteen out of 24 were published between 2007 and 2010. In total 5161 patients were studied (3804 HD and 1507 PD). The studies originated from 17 different countries: China (5), Japan (5), Brazil (3), Malaysia (2), South Korea (2), Germany (2), Italy (1), United Kingdom (1), United States of America (1), Brunei (1), Poland (1), Turkey (1), Serbia, Australia (1), Sweden (1), Belgium (1) and Taiwan (1). Ten studies looked at both dialysis modalities; 16 studies looked exclusively at HD patients and five studies looked exclusively at PD patients. Sample sizes were between 9 and 684 (HD) and 19 and 204 (PD) . Across all patients, the primary causes of end stage renal disease were hypertension, diabetes mellitus and glomerulonephritis. Ten studies included at least one control group, half of which recruited age and gender matched non-dialysis patients. Sixty-three percent of the articles looked at multiple GI symptoms; 27% looked solely at constipation and 10% looked at diarrhoea, steatorrhea, IBS or dyspepsia.
Outcomes were assessed subjectively in 27 studies. Three studies 14, 19, 25 used objective measures, including electrogastrography (EGG), C-octanoic acid breath test and faecal analysis, but only one of these studies included patient reported symptoms. 14 Validated measuring tools were used in 20 studies. Six provided descriptions of the definitions used for symptom diagnosis. Only three studies included dietary data. Medications were considered in 53% of the studies; the most common were laxatives, acid-suppressors and phosphate binders.
NOS quality assessment Table 2 shows the quality assessment of the included studies using the NOS tool. For cross sectional studies, 11 out of 24 scored >7 out of 8 (good quality), 9 scored 5-6 out of 8 (fair quality) and 4 scored less than 4 out of 8 (poor quality). For cohort studies, 4 out of 6 scored >8 out of 10 (good quality), 1 scored 6 or 7 out of 10 (fair quality) and 1 scored less than 6 out of 10 (poor quality).
Eight studies had truly randomized or unselected populations, 19 had sample sizes that were considered 'somewhat representative' of the dialysis population, and three studies had very select populations, or no description of the participants. Outcome assessment was the weakest component for all studies, as almost all of the diagnostic tools were subjective or patient-reported.
Diagnostic tools
Non-validated patient administered questionnaires were used in nine studies. The Gastrointestinal Symptom Rating Scale (GSRS) was used six times and was the most validated tool used, with strong inter-rater reliability. 33 The Rome II (for functional bowel disorders) and Rome III (for IBS) criteria were also used in two and four studies respectively. Two studies diagnosed symptoms through an interview process and two used the Gastrointestinal Symptom Questionnaire (GSQ). Other methods of diagnosis included laboratory stool analysis, Izumo Scale, 34 Bristol Stool Chart 35, 36 an unspecified validated questionnaire and laxative use as a surrogate marker for constipation.
Prevalence of GI symptoms
All GI symptoms
The most prevalent symptoms in all dialysis patients were constipation, indigestion, abdominal pain and reflux. The ranges of symptom prevalence can be seen in Table 3 . Constipation was the most frequently discussed symptom, mentioned in 24 studies. Fourteen out of 24 looked at HD patients, with prevalence ranging from 1.6% 10 to 71.7%. 2 Eight studies looked at PD patients, where prevalence ranged from 14.2% 17 to 90.3%. 20 Constipated dialysis patients were found to have lower HR-QoL scores, 2 and constipated PD patients were also at greater risk of peritonitis. 24 Symptom prevalence sensitive analysis for studies with Newcastle Ottawa Score >5, and for studies using the GSRS are presented in tables 4 and 5 respectively.
Dialysis patients versus non-dialysis controls
Five studies contrasted the prevalence of symptoms between dialysis and non-dialysis patients.
8-10,16,23 Vomiting was reported significantly more in those having dialysis regardless of modality. [8] [9] [10] 16 Dialysis patients were also reported to have more IBS than control groups. 8,10,16 Strid et al. comparing 183 dialysis patients to healthy controls from the general population found that those on dialysis had higher GSRS scores for every component except reflux. 23 
HD vs. PD
Five studies contrasted the prevalence of constipation between HD and PD patients, four finding it was more common in HD. 2, 8, 12, 26 In a study conducted by Yasuda et al. 26 which included 261 HD and 204 Continuous Ambulatory Peritoneal Dialysis (CAPD) patients, HD patients were found to have a 3.14 times increased risk of constipation compared to those on PD, with low dietary fibre intakes and the use of ion exchange resins being independent risk factors. 26 Self-reporting in diaries
• 38% taking laxatives / cathartics for chronic constipation 8 Table 2 Quality assessment of the included studies for selection, comparability and outcome, by total score (NB. Modified Newcastle Ottawa Scale (NOS) for cross-sectional studies).
Cross-sectional studies (total out of 8) Cohort studies (total out of 10)
Author ( Peritoneal dialysis patients reported significantly more nausea, vomiting, bloating, early satiety, anorexia, diarrhoea and heartburn than HD patients in the study by Salamon. 21 Constipation was the only symptom that was not significantly different between the two modalities. 21 In addition, 53% of PD patients compared with 14% of HD patients reported decreased food intake as a result of GI symptoms and 34% of PD versus 9% of HD patients reported changing their diet to alleviate their symptoms. 21 Interestingly, three studies reported that abdominal pain was more common in those having HD. 8, 12, 16 Three out of four articles reported a higher prevalence of reflux in PD patients, 12, 20, 23 than HD.
Severity and impact of GI symptoms
Symptom severity was measured in 11 studies, using the GSRS, GSQ, Izumo Scale, or patient interviews. The impacts of these symptoms on health rated quality of life (HR-QoL) were measured in four studies, using the Kidney Disease Quality of Life Questionnaire, the SF-12 and SF-36 or the Becks Depression Scale. Constipation diminished the HR-QoL in all dialysis patients, but affected those on PD more profoundly. 2 Li et al. found PD patients who changed their diets as a result of GI symptoms were more likely to be diagnosed as malnourished through the Subjective Global Assessment (SGA).
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DISCUSSION
This systematic review confirmed that GI symptoms are important, as they are highly prevalent and a significant patient symptom burden in the dialysis population. However, the underlying causes have been poorly studied. This systematic review included 30 studies comprising 24 cross-sectional and six cohort studies, all published between 1998 and 2016. Only three studies used objective measures of bowel function or GI symptoms, whereas subjective measures were assessed in 27 out of 30 studies. Sixty-three percent of the articles looked at more than one GI symptom; 27% looked solely at constipation and 10% looked at one of diarrhoea, steatorrhea, IBS or dyspepsia.
Outcomes were matched to the study design, however, the applicability of the outcomes reported was undermined by inadequate depth of investigation into confounding factors such as diet and medication.
There was significant heterogeneity between the methodologies, populations, symptom definitions and diagnostic tools used by each study. Unsurprisingly, prevalence data for each GI symptom varied across the literature. Whether differences in symptom prevalence relate to dialysis technique, diet, medications or other factors is speculative, due to the lack of information included in the reviewed studies.
The GSRS was the most validated and useful tool used. 33 The GSRS provides insight into a large scope of symptoms and symptom severity. Other tools used included nonvalidated patient administered questionnaires and the Rome II (for functional bowel disorders) and Rome III (for IBS) criteria. Other methods of diagnosis included an interview process, GSQ, laboratory stool analysis, Izumo Scale, 34 Bristol Stool Chart, 35 an unspecified validated Table 5 The prevalence of gastrointestinal (GI) symptoms in haemodialysis (HD) and peritoneal dialysis (PD) patients, reported across the six studies that used the Gastrointestinal Symptom Rating Scale (GSRS) [11] [12] [13] 20, 23, 24 GI symptom Prevalence range in HD (%) Articles reporting on GI symptom prevalence in HD Prevalence range in PD (%)
Articles reporting on GI symptom prevalence in PD questionnaire and laxative use as a surrogate marker for constipation. Constipation, diarrhoea and indigestion were the most frequently assessed symptoms despite evidence that a broad range of GIT symptoms are reported in people on dialysis. A literature review in 2013 examined a limited range of GI symptoms in patients with advanced CKD, as well as those on dialysis and found similarly high prevalence ranges for constipation (16-51%), nausea (21-54%), diarrhoea (17-33%) and vomiting (11-23%) (**39). Most studies in the current review had a very narrow symptom focus, such as constipation, thereby potentially under-reporting or understating the importance of other GIT symptoms while overstating the importance of the reported symptom. This review highlights that other less reported symptoms such as indigestion, abdominal pain, bloating, reflux and IBS like symptoms, are also largely prevalent in patients on dialysis. In the limited number of studies that compared dialysis modality, constipation and abdominal pain were found to be more prevalent in HD patients, whereas reflux was more common in those on PD; however, the narrow symptom focus limits the generalizability of these results.
Limitations of the included studies
It is recognized that dialysis patients and GI symptoms are both methodologically difficult to study. Methodological limitations in all of the included studies reduced the overall quality and generalizability of results in the dialysis population. Seven out of 30 studies had a sample size less than 50, while others failed to truly represent the dialysis population, due to restrictive selection or omission criteria (such as patients with diabetes, who typically have more GI symptoms including gastroparesis). Considering symptoms without properly considering confounding factors such as diet and medications was a common limitation, introducing significant bias. Many studies did not report on or effectively control for confounding factors such as co-morbidities, anthropometry, gender, age, biochemistry and importantly medications and diet.
Almost half of the studies did not discuss the use of medications. Drugs such as phosphate binders are known to increase the prevalence of GI symptoms such as nausea, vomiting, dyspepsia, abdominal pain and constipation. 10, 37 Failure to report on laxative use may have also skewed the data for constipation and diarrhoea. The systematic prescription of laxatives is common in PD patients to prevent constipation related mechanical failures. This may in part explain the findings of lower prevalence of constipation in PD patients when compared to those on HD. In contrast, Ikee et al. 15 simply used laxative prescription as a surrogate marker of constipation irrespective of patient-reported symptoms or medication adherence. Reporting GI symptoms without considering the cause overlooks the possibility that the causes are potentially iatrogenic (medications or highly restrictive poorly planned diets). Importantly, it remains unclear if patients are experiencing symptoms despite medication use or if the most useful medications are being used correctly. Given the known positive and negative influence of some medications on bowel health this is a major limitation of a majority of the studies reviewed.
In addition, descriptive food intake data were not presented in any studies. Quantitative nutrient data was only reported in three studies. Yasuda et al. reported dietary fibre intakes of 5.9 and 11 g per day in HD and PD patients, respectively, 26 well below dietary guideline targets, and unsurprisingly a high prevalence of constipation. Dialysis patients are often advised to restrict their intake of fruits, vegetables, whole grains and other fibre-rich foods to restrict potassium intake. 38 Therefore, describing symptoms without considering dietary intake undermines the value of these studies and overlooks the potential of dietary interventions to improve symptom burden. This is even more important given that a recent meta-analysis suggests a more plant-based, fibre-rich diet (with less animal protein, sodium and added sugars) may decrease mortality risk, 38 and is also likely to provide benefits to GI health.
Future studies of gastrointestinal symptom burden therefore should include the collection of dietary intake data using tools such as 24 h recalls and Food Frequency Questionnaires (FFQs), to avoid conclusions that overlook the potential true causes. Another limitation of these studies was that they were primarily observational and captured only a 'snapshot' of symptom prevalence. Symptom severity and frequency was poorly documented. Studies also classified symptom prevalence over different time frames (e.g. today, past 2 weeks and past 12 months). Research assessing the prevalence of symptoms over time would be valuable, as it could provide insight into when and why GI symptoms occur or develop.
Very few interventional studies were identified in this review, although interventional studies were not a specific focus and some may have been excluded through the search process. Randomized controlled trials used mostly objective validated measures, whereas outcomes in observational studies were commonly subjective patient reports and nonvalidated questionnaires. Although patient reported outcomes are very important, the way that questions are asked in these scenarios can introduce significant bias, especially when asking about symptoms such as constipation or diarrhoea as opposed to stool consistency, frequency and urgency. The studies using objective measures mostly reported on sub-clinical markers and did not describe patient reported symptoms. Furthermore, the definitions of each GI symptom were variable and depended on the diagnostic tool used. Symptom severity was generally overlooked. The studies that did assess severity used Likert scales with differing ranges (from zero to one, one to five and one to seven), or used low thresholds to define symptom presence and thus offer little insight into symptom burden.
Although GI symptoms have been associated with reduced Quality of Life (QoL) in many clinical scenarios, there was a lack of studies looking at GI symptom burden and QoL in the papers in this review.
Limitations of the review
It is acknowledged that this review has its limitations. This review was limited to the English language, which may have resulted in language bias. It is possible that studies using generic questionnaires to look at GI symptom prevalence were missed if these symptoms were not reported in abstracts or keywords, however, our search did not identify any studies in dialysis patients that used these tools. We included detailed conference abstracts in this review to encapsulate all current literature, but this may have resulted in bias by missing key information relevant to those studies. Also, the ranges we reported for symptom prevalence are of limited value, due to significant heterogeneity across the studies in methodology, symptom definitions, thresholds and time frames for diagnosis.
In conclusion, this review confirms that a high prevalence and wide range of GI symptoms are being experienced by dialysis patients, but the causes remain unclear. Although frequently reported, the prevalence and severity of each symptom remains unclear due to heterogeneity in the literature. Important confounders of GI symptoms such as diet quality and medications were generally overlooked. Diet quality and medications therefore should be included in future research to enhance our understanding of the impacts that these symptoms have on dialysis patients, as well as the factors that may contribute to their prevalence.
